 |
인쇄하기
취소
|
Yungjin Pharm introduces D-Pharm's new stroke medication
Yungjin Pharm said on October 20 it had concluded an exclusive licensing agreement with D-Pharm, an Israel based drug company, to introduce D-Pharm's proprietary ethical agent (DP-b99) for the treatment of acute stroke.
DP-b99 is a unique neuroprotective drug that addresses the array of damaging processes occurring in the brains of stroke patients. The current double blind, placebo controlle...
DP-b99 is a unique neuroprotective drug that addresses the array of damaging processes occurring in the brains of stroke patients. The current double blind, placebo controlle...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.